These findings are consistent with the anti-tumour effects of RRM2 inhibition in pancreatic,38 cervical29 and breast cancer39 as well as in neuroblastoma40 and glioblastoma.41 It further suggests that RRM2 may be an interesting therapeutic target in the context of ACC. Here, RRM2 is linked to adrenal cortex carcinoma.